The acquisition of six FDA-approved drugs from WraSer and Xspire Pharma will provide Blue Water Biotech with additional revenue streams and strengthen its financial position. This will also help the company advance its vaccine pipeline, which is focused on addressing significant global health challenges. As a result, the stock price is likely to go up in the short term.